Received May 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | — | OT |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | OT |
t after receiving his second dose of MMR-II, the patient "developed a rash and had fevers."; t after receiving his second dose of MMR-II, the patient "developed a rash and had fevers."; This spontaneous report was received from patient's grandmother and refers to a(n) 6-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with the second dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), Injection 0.5 mL administered by intramuscular route (lot # and expiration date were not reported) as prophylaxis which was diluted with a sterile diluent (expiration date, and lot # were not reported). On an unknown date, after receiving his second dose of this vaccine, he developed a rash and had fevers. No other symptoms were reported by the patient's grandmother. The patient received some fever medication as treatment. The patient recovered from the events on an unspecified date. The causal relationship between the events and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) was not provided.